| BAY 63-2521 |
|
| (CAS 625115-55-1) |
 |
| Description： |
Riociguat (BAY 63-2521) is a novel drug that is currently in clinical development by Bayer. It is a stimulator of soluble guanylate cyclase (sGC). At the moment Phase III clinical trials investigate the use of riociguat as a new approach to treat two forms of pulmonary hypertension (PH): chronic thromboembolic pulmonary hypertension (CTEPH) and pulmonary arterial hypertension (PAH). Riociguat constitutes the first drug of a novel class of sGC stimulators.
|
| Product No. |
KT00158 |
| Product Name |
BAY 63-2521 |
| Synonyms |
BAY632521 |
| Formal Name |
|
| CAS Number |
625115-55-1 |
| Molecular Formula |
QNZC20H19FN8O2 |
| Formula Weight |
422.42 |
| Formulation |
A crystalline solid |
| Purity |
98%min |
| Stability |
2 years |
| Storage |
-20°C |
| Shipping |
USD45 for Europe and USA. No shipping charge once amount reach USD500 |
| Quality Control |
HNMR,CNMR,LCMS,HPLC,IR,etc. |
| Price & Availability |
In Stock. Price Negotiated. |
|
| Related Products： |
(+)-JQ-1
AG1024
A 769662
Ansamitocin P 3
AG-490
AZ 23
A 922500
AZD5363
|
|
